A huge buying opportunity, page-8

First 8 Last

Share
Profile

Follow
Kiwinvestor

604 Posts.

140

26/02/21

12:30

Post #: 51359185
Share

Originally posted by Senpras89: ↑

Thanks Kiwinvestor, yes on a paper money basis there has been a loss, but I do not look at the stock every day and you cant lose something you haven't sold - this is a hold and keep type stock.

My long term view is around a few simple points, I try to have a very clear thesis:

1) I have a lot of confidence and conviction in the stock given that most of my direct family are in the medical profession and can vouch for the scientific data.

2) I know people in the trials who can attest to a very material improvement in their function - which provides real life data.

3) Paul Rennie's journey to start this company was unbelievable and demonstrated very high conviction. He is a man of integrity and I have know him reasonably well. I've never seen him worried about PAR, and has a quiet confidence. I genuinely think it was unbelievable he got a raise done during those market conditions.

So I genuinely thought in 2020, and still think, that $4 was extremely low to be selling off something of such tremendous value. Value and timelines rarely intersect and this is a deep value play. This should be at minimum ~$1bn given the data that has already come out, I have never seen data that significant come out before a major trial.

What value that will be in 3 years is difficult to analyse, it depends on multiple behavioural factors, given that this essentially "pre-revenue". In the medium term it will require just a change in thinking for newer investors wanting to invest in the stock.

1. The changing market view that it is an "a-typical" biotech stock with a totally different risk profile.
2. People having a collective capacity to hold stocks through market cycles.
3. That institutions like Morgans actually understand the stock before building models that omit numerous details, and then fear monger people into selling because those people do not have all the information.

Everyone will have their back-of the envelope style valuation for this.
Whatever number that comes to easily suggests it to be much more than $4. It would be irresponsible of me to say it will be over $15, but it has that potential and more.

Expand

Thanks, appreciate the reply.

PAR Price at posting: $2.44 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

What's causing the cost-of-living crisis, and how to navigate it

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

There are more pages in this discussion • 56 more messages in this thread...

First 8 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 26.5¢		Change 0.000(0.00%)		Mkt cap ! $92.81M

Open	High	Low	Value	Volume
27.0¢	29.0¢	25.5¢	$355.3K	1.299M

Buyers (Bids)

No.	Vol.	Price($)
6	71853	26.0¢

Sellers (Offers)

Price($)	Vol.	No.
26.5¢	26910	2

View Market Depth

No.	Vol.	Price($)
6	71853	0.260
8	100558	0.255
9	143721	0.250
5	44300	0.245
7	140803	0.240

Price($)	Vol.	No.
0.265	26910	2
0.270	30436	6
0.275	40217	5
0.280	30175	6
0.285	51500	2

Last trade - 12.56pm 18/10/2024 (20 minute delay)

PAR (ASX) Chart

A huge buying opportunity, page-8

What's causing the cost-of-living crisis, and how to navigate it

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Sierra Nevada raises $2M for silver exploration at Blackhawk

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

A huge buying opportunity, page-8

Top Stories

What's causing the cost-of-living crisis, and how to navigate it

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Sierra Nevada raises $2M for silver exploration at Blackhawk

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News